ACET

Adicet Bio Inc

3.05

Nov 06 • 3:59 PM ET +0.13 (4.45%)

3.05

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Nov 05, 9:50 PMAdicet Bio posts Q3 2026 non-GAAP EPS -$1.76 (+62% YoY), revenue $0, misses EPS, beats revenue estimates, confirms pivotal prula-cel lupus nephritis study start

Peers: INAB FATE CABA KYTX ALLO CRBU NKTX SANA IPSC CRSP

| Held by: VTI VXF IWC DFMC DFAS AVSC BTEC DXUV CHNA

Scroll to Statements

Index	-
Market Cap	28.55M
Enterprise Value	-60.29M
Income	-91.00M
Sales	0.00M
Book/sh	10.97
Cash/sh	10.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	102
IPO	Jan 26, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.28
P/C	0.28
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.09
Current Ratio	6.09
Debt/Eq	0.12
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	-8.57
EPS next Y	-4.95
EPS next Q	-1.79
EPS this Y	57.15%
EPS next Y	31.87%
EPS next 5Y	44.32%
EPS past 3/5Y	14.57% 26.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	57.60%
Sales Y/Y TTM	-
EPS Q/Q	62.76%
Sales Q/Q	-
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-11.54% -

Insider Own	12.22%
Insider Trans	0.00%
Inst Own	54.38%
Inst Trans	2.10%
ROA	-67.55%
ROE	-85.91%
ROIC	-81.28%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-24.74%
SMA50	-53.46%
SMA200	-59.68%
Trades

Shs Outstand	9.36M
Shs Float	8.22M
Short Float	6.35%
Short Ratio	2.50
Short Interest	0.52M
52W High	11.37 -73.19%
52W Low	2.87 6.27%
Volatility	8.29% 8.38%
ATR (14)	0.38
RSI (14)	19.57
Beta	1.75
Rel Volume	1.21
Avg Volume	209.17K
Volume	254,064

Perf Week	-10.82%
Perf Month	-46.86%
Perf Quarter	-62.39%
Perf Half Y	-64.33%
Perf YTD	-63.78%
Perf Year	-71.83%
Perf 3Y	-86.67%
Perf 5Y	-97.93%
Perf 10Y	-
Recom	1.00
Target Price	29.00
Prev Close	2.92
Price	3.05
Change %	4.45%

Consensus

Strong Buy

Avg. Price Target

$29.00

Implied Upside

+850.8%

Analysts11incl. previous ratings

Rating Distribution8 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 05, 2026	Resumed	JJefferies	Buy	$19	+523.0%
Sep 30, 2024	Resumed	GGuggenheim	Buy	$7	+129.5%
Sep 11, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral
Jun 27, 2023	Downgrade	JJMP Securities	Mkt Outperform → Mkt Perform
Jun 27, 2023	Downgrade	GGuggenheim	Buy → Neutral
Jun 01, 2023	Downgrade	JJP Morgan	Overweight → Neutral	$20 → $6	+96.7%
Sep 21, 2022	Initiated	JJP Morgan	Overweight	$23	+654.1%
Mar 31, 2022	Initiated	SSMBC Nikko	Outperform	$28	+818.0%
Mar 08, 2022	Initiated	TTruist	Buy	$30	+883.6%
Mar 04, 2022	Initiated	JJefferies	Buy	$27	+785.2%
May 18, 2021	Initiated	BBTIG Research	Buy	$34	+1,014.8%
Apr 23, 2021	Initiated	HH.C. Wainwright	Buy	$27	+785.2%
Apr 14, 2021	Initiated	CCanaccord Genuity	Buy	$28	+818.0%
Apr 08, 2021	Initiated	GGuggenheim	Buy	$22	+621.3%
Nov 04, 2020	Initiated	RB. Riley Securities	Buy	$30	+883.6%
Oct 27, 2020	Initiated	JJMP Securities	Mkt Outperform	$30	+883.6%
Oct 16, 2020	Initiated	WWedbush	Outperform	$25	+719.7%

Nov-05-26 04:10PM	Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates (Business Wire) -5.81%
Oct-30-26 05:38PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.43%
Oct-22-26 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire) -6.78%
Sep-30-26 07:12PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Sep-28-26 10:54AM	Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance (InvestorsHub) -29.60%
08:13AM	Loading…
08:13AM	Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients (InvestorsHub)
06:45AM	Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis (Business Wire)
Sep-25-26 04:00PM	Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis (Business Wire) +9.07%
Sep-02-26 04:00PM	Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
Sep-01-26 07:00AM	Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update (Business Wire) +6.44%
Aug-31-26 05:39PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-26 04:00PM	Adicet Bio Announces FDA Clearance of IND Application for ADI-212 (Business Wire)
Aug-05-26 04:15PM	Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates (Business Wire) -13.43%
Jul-21-26 04:00PM	Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference (Business Wire) +5.54%
May-14-26 04:00PM	Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference (Business Wire) -8.68%
04:01PM	Loading…
May-13-26 04:01PM	Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
Mar-12-26 04:00PM	Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress (Business Wire) -5.76%
Jan-30-26 07:00AM	Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire) -6.00%
Jan-07-26 07:00AM	Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones (Business Wire)
Dec-26-25 08:30AM	Adicet Bio Announces Reverse Stock Split (Business Wire)
Nov-28-25 02:23PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.85%
Nov-05-25 04:01PM	Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-31-25 04:59PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-28-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference (Business Wire) -5.12%
Oct-16-25 07:00AM	Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) (Business Wire) +5.49%
Oct-07-25 09:40AM	Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? (Zacks) -14.69%
07:01AM	Adicet Bio, Inc. Announces $80 Million Registered Direct Offering (Business Wire)
06:45AM	Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) (Business Wire)
Sep-30-25 04:27PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks)
07:00AM	Loading…
Sep-02-25 07:00AM	Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-29-25 04:48PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.09%
Aug-12-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's Why (Zacks) +7.14%
Aug-07-25 04:01PM	Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.62%
Aug-06-25 04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference (Business Wire)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-25-25 07:27AM	Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 (Clinical Trials Arena)
Jul-24-25 07:00AM	Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
May-21-25 04:00PM	Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference (Business Wire) -6.59%
May-09-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks) +27.49%
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.44% -18.65%
Apr-30-25 04:47PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.41% -5.07%
07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-28-25 04:30PM	Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Business Wire) +5.82%
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire) -7.96%
Mar-31-25 05:12PM	Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.06%
07:00AM	Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Mar-23-25 08:43AM	Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-06-25 04:01PM	Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress (Business Wire) -5.90%
Mar-03-25 07:00AM	Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting (Business Wire) -5.70%
Feb-27-25 08:36AM	Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 (Investing.com)
07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) (Business Wire)
Feb-05-25 07:10AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement (Business Wire) +9.79%
Jan-31-25 06:06PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-08-25 04:10PM	Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones (Business Wire)
Dec-31-24 04:48PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Dec-19-24 07:00AM	Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Dec-18-24 07:00AM	Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer (Business Wire) -6.28%
Nov-29-24 04:44PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 04:00PM	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.42%
07:00AM	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
Nov-16-24 09:00AM	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-06-24 04:00PM	Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 07:00AM	Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-01-24 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Oct-17-24 07:27AM	Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials (TipRanks)
Oct-16-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome (Business Wire) +6.43%
Sep-30-24 05:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Business Wire)
07:00AM	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases (Business Wire)
Sep-19-24 07:00AM	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue (Business Wire)
Aug-30-24 05:44PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-24 04:00PM	Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -7.84%
Aug-19-24 07:00AM	Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors (Business Wire)
Aug-13-24 07:00AM	Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Aug-01-24 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 05:25PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-24 01:24AM	Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-09-24 09:52AM	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag (Zacks)
07:34AM	Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment (Pharmaceutical Business Review)
Jul-08-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +9.35%
Jun-28-24 05:00PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.70%
Jun-24-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Business Wire) +9.49%
Jun-21-24 11:10AM	Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-05-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis (Business Wire) +5.88%
May-31-24 05:41PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference (Business Wire) -7.05%
May-14-24 09:54PM	ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 (InvestorPlace) -7.64% +5.26%
04:01PM	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
10:00AM	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
May-07-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-30-24 05:10PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.29%
Apr-22-24 04:30PM	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Business Wire)
Apr-08-24 07:00AM	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Apr-04-24 08:38AM	Why Adicet Bio (ACET) Stock Might be a Great Pick (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 20 '26	Buy	7.27	74,751	543,440	1,182,624	Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 19 '26	Buy	7.21	74,268	535,472	1,107,873	Apr 13 05:20 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Feb 18 '26	Buy	7.04	74,577	525,022	1,033,605	Apr 13 05:20 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 08 '26	Sale	6.42	72,939	468,082	0	Apr 09 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 07 '26	Sale	6.52	31,719	206,765	32,523	Apr 09 05:38 PM
OrbiMed Genesis Master Fund, L	Shareholder	Apr 09 '26	Proposed Sale	6.55	78,499	514,168		Apr 09 05:34 PM
OrbiMed Israel Partners II, L.	Shareholder	Apr 08 '26	Proposed Sale	6.55	40,416	264,725		Apr 08 08:14 PM
OrbiMed Israel Partners Limite	Shareholder	Apr 07 '26	Proposed Sale	6.43	64,242	413,076		Apr 07 08:46 PM

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Senior VP & Chief Scientific OfficerDr. Blake Aftab Ph.D.

Ph.D.Dr. Lloyd Klickstein M.D.

Chief Financial OfficerMr. Brian Nicholas Harvey M.B.A.

Chief Technology OfficerDr. Donald Healey Ph.D.

Chief Human Resource OfficerMs. Amy Locke

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACET

Adicet Bio Inc

Upgrade your Finviz experience